Malaysia
Search
Sign In
Change Password
Points
Sign Out
Urology
Top Medical News
Consuming organic foods exclusively as well as practicing intermittent fasting may help lower the risk erectile dysfunction, a study suggests.
Day temperature difference appears to influence lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH), such that the greater the difference, the worse the LUTS symptoms are and the higher the tendency to visit the emergency room is, a study reports.
Patients with erectile dysfunction (ED) have elevated values of atherogenic index of plasma (AIP), a recent study has found.
An impaired forced expiratory volume in 1 second appears to correlate with erectile dysfunction independently of other classic risk factors, a recent study has found.
Treatment with vibegron 75 mg once daily effectively lowers micturitions, urgency episodes, and urge incontinence and increases the volume per micturition in patients with symptoms of overactive bladder (OAB), results of an international phase III study have shown. It is also safe and well tolerated.
High-risk human papilloma virus (HPV) infection occurs rarely in patients with squamous cell carcinoma of the bladder, despite having an aggressive histologic subtype, a study has found.
Treatment with 5-alpha reductase inhibitor is associated with a reduced risk of surgical intervention in men with benign prostatic hyperplasia (BPH), a recent study has shown. Patients also show high medication adherence outside of clinical trials.
Special Reports
The incidence of prostate cancer (PC) and cardiovascular disease (CVD) typically increases with age; therefore, the choice of treatment for PC should take into account a patient’s underlying cardiovascular conditions. In this interview, Professor Laurence Klotz shared his take on androgen deprivation therapy (ADT) options for patients with prostate cancer who are at-risk of CV events.
At the Eisai-sponsored tea symposium during the 27th Malaysian Urological Conference at Shangri-La Kuala Lumpur, Professor Osamu Yokoyama highlighted the advantages of silodosin (Urief®, Eisai Inc.) in relieving lower urinary tract symptoms associated with benign prostate hyperplasia.
Conference Reports
The addition of the potent triple angiokinase inhibitor nintedanib to a standard chemotherapeutic regimen consisting of gemcitabine and cisplatin generated survival benefit in patients with locally advanced muscle invasive bladder cancer (MIBC), according to the results of the NEO-BLADE* trial presented at ASCO GU 2020. However, the study failed to demonstrate improvement in the primary endpoint of pathologic complete response (CR).
The use of sipuleucel-T significantly prolongs overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), regardless of treatment setting, based on real-world data presented at ASCO GU 2020.
A combination therapy of enfortumab vedotin and pembrolizumab shows promising activity, with rapid and durable responses in the first-line setting for patients with metastatic urothelial carcinoma (mUC) ineligible to receive cisplatin, according to updates from the EV-103* study presented at GUCS 2020.
Patients with previously treated advanced or metastatic clear cell renal cell carcinoma (RCC) appear to derive greater overall survival (OS) benefit with nivolumab compared with everolimus, according to final results of the phase III CheckMate 025* trial presented at ASCO GU 2020.
An electronic surveillance tool generated better compliance and satisfaction rates than standard in-person care among men with stage 1 testicular cancer, according to the interim results of the WATChmAN* trial presented at ASCO GU 2020.
While combining docetaxel with androgen deprivation therapy (ADT) is known to improve survival for advanced prostate cancer, its role in the setting of adjuvant treatment given after radical radiotherapy plus ADT for the treatment of intermediate- and high-risk prostate cancer was proven otherwise — both in terms of biochemical disease-free survival (BDFS) and quality of life (QoL), according to the SPCG*-13 trial presented at the 2020 Genitourinary Cancer Symposium (GUCS).
The addition of apalutamide, a novel androgen receptor inhibitor, to androgen deprivation therapy (ADT) reduced the risk of progression while on first subsequent therapy or death (PFS2) in men with metastatic castration-sensitive prostate cancer (mCSPC), according to exploratory analysis of the phase III TITAN* trial.
